

Jason K Sicklick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9289671/publications.pdf>

Version: 2024-02-01

108
papers

4,130
citations

117453

34
h-index

133063

59
g-index

109
all docs

109
docs citations

109
times ranked

6702
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. <i>Nature Medicine</i> , 2019, 25, 744-750.	15.2	443
2	Prevalence of <i>PDL1</i> Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. <i>JAMA Oncology</i> , 2018, 4, 1237.	3.4	214
3	Analysis of <i>NTRK</i> Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for <i>NTRK</i> -Targeted Therapeutics. <i>JCO Precision Oncology</i> , 2018, 2018, 1-20.	1.5	201
4	Epidemiology of Gastrointestinal Stromal Tumors in the Era of Histology Codes: Results of a Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 298-302.	1.1	190
5	NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1604-1612.	2.3	175
6	Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. <i>Nature Communications</i> , 2020, 11, 4965.	5.8	172
7	<i>FGFR1</i> and <i>NTRK3</i> actionable alterations in "Wild-Type" gastrointestinal stromal tumors. <i>Journal of Translational Medicine</i> , 2016, 14, 339.	1.8	167
8	<i>ARID1A</i> alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. , 2020, 8, e000438.		117
9	Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. <i>Nature</i> , 2016, 534, 407-411.	13.7	114
10	Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma. <i>JAMA Surgery</i> , 2016, 151, 365.	2.2	102
11	Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 6248-6256.	3.2	89
12	Diminished Survival in Patients with Bile Leak and Ductal Injury: Management Strategy and Outcomes. <i>Journal of the American College of Surgeons</i> , 2018, 226, 568-576e1.	0.2	84
13	<i>GPR68</i> , a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. <i>FASEB Journal</i> , 2018, 32, 1170-1183.	0.2	83
14	Improved Perioperative Outcomes With Minimally Invasive Distal Pancreatectomy. <i>JAMA Surgery</i> , 2014, 149, 237.	2.2	81
15	Molecular Pathways: Targeting the Microenvironment of Liver Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 6390-6399.	3.2	79
16	Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. <i>Annals of Surgical Oncology</i> , 2016, 23, 134-141.	0.7	76
17	Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2018, 23, 586-593.	1.9	75
18	Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. <i>Journal of the American College of Surgeons</i> , 2016, 222, 480-490.	0.2	71

#	ARTICLE	IF	CITATIONS
19	Platelet-Derived Growth Factor Receptor- α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1. <i>Gastroenterology</i> , 2015, 149, 420-432.e16.	0.6	68
20	Targeting ARID1A mutations in cancer. <i>Cancer Treatment Reviews</i> , 2021, 100, 102287.	3.4	63
21	Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study. <i>Cancer</i> , 2015, 121, 2960-2967.	2.0	60
22	TGF- β 1-mediated transition of resident fibroblasts to cancer-associated fibroblasts promotes cancer metastasis in gastrointestinal stromal tumor. <i>Oncogenesis</i> , 2021, 10, 13.	2.1	53
23	Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2553-2562.	1.9	50
24	Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 263-275.	2.7	49
25	Population-Based Epidemiology and Mortality of Small Malignant Gastrointestinal Stromal Tumors in the USA. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1132-1140.	0.9	48
26	Small bowel volvulus in the adult populace of the United States: results from a population-based study. <i>American Journal of Surgery</i> , 2015, 210, 201-210.e2.	0.9	47
27	Long-Term Health-Related Quality of Life after Iatrogenic Bile Duct Injury Repair. <i>Journal of the American College of Surgeons</i> , 2014, 219, 923-932.e10.	0.2	46
28	Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. <i>Genome Medicine</i> , 2021, 13, 155.	3.6	44
29	The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling. <i>Journal of Surgical Research</i> , 2014, 187, 377-385.	0.8	42
30	Outcomes after resection of cortisol-secreting adrenocortical carcinoma. <i>American Journal of Surgery</i> , 2016, 211, 1106-1113.	0.9	42
31	Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence. <i>Annals of Surgical Oncology</i> , 2016, 23, 126-133.	0.7	42
32	Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. <i>International Journal of Cancer</i> , 2021, 148, 702-712.	2.3	41
33	Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 1997-2006.	0.9	39
34	Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit?. <i>Annals of Surgical Oncology</i> , 2016, 23, 708-713.	0.7	38
35	Curative Surgical Resection of Adrenocortical Carcinoma. <i>Annals of Surgery</i> , 2017, 265, 197-204.	2.1	38
36	Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. <i>Journal of Surgical Oncology</i> , 2015, 112, 164-172.	0.8	36

#	ARTICLE	IF	CITATIONS
37	Actual 10-year survivors following resection of adrenocortical carcinoma. <i>Journal of Surgical Oncology</i> , 2016, 114, 971-976.	0.8	36
38	Cholecystectomy During the Third Trimester of Pregnancy: Proceed or Delay?. <i>Journal of the American College of Surgeons</i> , 2019, 228, 494-502e1.	0.2	33
39	Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression. <i>Oncotarget</i> , 2016, 7, 78226-78241.	0.8	29
40	MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages. <i>Oncogene</i> , 2019, 38, 5599-5611.	2.6	29
41	Minimally Invasive Resection of Adrenocortical Carcinoma: a Multi-Institutional Study of 201 Patients. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 352-362.	0.9	27
42	Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics. <i>Clinical Cancer Research</i> , 2021, 27, 2792-2797.	3.2	27
43	Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor. <i>Journal of Translational Medicine</i> , 2014, 12, 41.	1.8	26
44	Surgical Management of Adolescents and Young Adults With Gastrointestinal Stromal Tumors. <i>JAMA Surgery</i> , 2017, 152, 443.	2.2	25
45	Clinical Score Predicting Long-Term Survival after Repeat Resection for Recurrent Adrenocortical Carcinoma. <i>Journal of the American College of Surgeons</i> , 2016, 223, 794-803.	0.2	24
46	Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 525-535.	2.7	23
47	Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. <i>Oncogene</i> , 2021, 40, 1957-1973.	2.6	22
48	Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens. <i>JCI Insight</i> , 2021, 6, .	2.3	20
49	International Surgical Residency Electives: A Collaborative Effort From Trainees to Surgeons Working in Low- and Middle-Income Countries. <i>Journal of Surgical Education</i> , 2014, 71, 694-700.	1.2	19
50	Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database. <i>Annals of Surgical Oncology</i> , 2018, 25, 2308-2315.	0.7	19
51	High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment. <i>International Journal of Cancer</i> , 2021, 148, 2839-2847.	2.3	19
52	Development of a Soluble KIT Electrochemical Aptasensor for Cancer Theranostics. <i>ACS Sensors</i> , 2021, 6, 1971-1979.	4.0	19
53	Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns. <i>Oncologist</i> , 2021, 26, 787-796.	1.9	19
54	Academic Surgical Oncologists' Productivity Correlates with Gender, Grant Funding, and Institutional NCI Comprehensive Cancer Center Affiliation. <i>Annals of Surgical Oncology</i> , 2018, 25, 1852-1859.	0.7	18

#	ARTICLE	IF	CITATIONS
55	Cost-effectiveness Analysis of Genetic Testing and Tailored First-Line Therapy for Patients With Metastatic Gastrointestinal Stromal Tumors. <i>JAMA Network Open</i> , 2020, 3, e2013565.	2.8	17
56	Loss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma. <i>Journal of Translational Medicine</i> , 2019, 17, 246.	1.8	16
57	Incidence of Perioperative Complications Following Resection of Adrenocortical Carcinoma and Its Association with Long-term Survival. <i>World Journal of Surgery</i> , 2016, 40, 706-714.	0.8	15
58	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. <i>Annals of Surgical Oncology</i> , 2018, 25, 520-527.	0.7	15
59	Diagnostic Accuracy of Preoperative Gadoteric Acid-enhanced 3-T MR Imaging for Malignant Liver Lesions by Using Ex Vivo MR Imaging-matched Pathologic Findings as the Reference Standard. <i>Radiology</i> , 2015, 276, 775-786.	3.6	14
60	Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. <i>International Journal of Cancer</i> , 2020, 146, 3450-3460.	2.3	14
61	Duodenal-jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic <i>NF1</i> and Notch Pathway Mutations. <i>JCO Precision Oncology</i> , 2017, 2017, 1-12.	1.5	13
62	A Novel <i>PRKAR1B-BRAF</i> Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 238-242.	2.3	13
63	Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity. <i>Clinical Cancer Research</i> , 2021, 27, 5334-5342.	3.2	13
64	Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance. <i>Clinical Cancer Research</i> , 2017, 23, 6733-6743.	3.2	12
65	Blood Transfusion and Survival for Resected Adrenocortical Carcinoma: A Study from the United States Adrenocortical Carcinoma Group. <i>American Surgeon</i> , 2017, 83, 761-768.	0.4	12
66	Features of synchronous versus metachronous metastasectomy in adrenal cortical carcinoma: Analysis from the US adrenocortical carcinoma database. <i>Surgery</i> , 2020, 167, 352-357.	1.0	11
67	Anti-KIT DNA Aptamer for Targeted Labeling of Gastrointestinal Stromal Tumor. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1173-1182.	1.9	11
68	Cumulative GRAS Score as a Predictor of Survival After Resection for Adrenocortical Carcinoma: Analysis From the U.S. Adrenocortical Carcinoma Database. <i>Annals of Surgical Oncology</i> , 2021, 28, 6551-6561.	0.7	11
69	Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: Retrospective analysis of an International Patient Registry. <i>Journal of Surgical Oncology</i> , 2019, 120, 715-721.	0.8	10
70	KITlow Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2035-2048.	1.9	10
71	Personalized, molecularly matched combination therapies for treatment-na.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2512-2512.	0.8	10
72	Synchronous metastatic colon cancer and the importance of primary tumor laterality – A National Cancer Database analysis of right- versus left-sided colon cancer. <i>American Journal of Surgery</i> , 2020, 220, 408-414.	0.9	9

#	ARTICLE	IF	CITATIONS
73	Gastric Plexiform Fibromyxoma. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1936-1939.	0.9	8
74	The Use of Solicited Publishing by Academic Surgeons. <i>Surgery</i> , 2018, 164, 212-218.	1.0	7
75	Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine. <i>JCO Precision Oncology</i> , 2022, 6, e2000508.	1.5	7
76	The prognostic significance of adrenocortical carcinomas identified incidentally. <i>Journal of Surgical Oncology</i> , 2018, 118, 1155-1162.	0.8	6
77	Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience. <i>Oncologist</i> , 2020, 25, e1803-e1806.	1.9	6
78	Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary. <i>JCO Precision Oncology</i> , 2021, 5, 1687-1698.	1.5	6
79	Rapidly progressive subcutaneous metastases from gallbladder cancer: insight into a rare presentation in gastrointestinal malignancies. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, E58-64.	0.6	5
80	Porta Hepatis Mass. <i>JAMA Surgery</i> , 2016, 151, 187.	2.2	4
81	Precision oncology: the intention-to-treat analysis fallacy. <i>European Journal of Cancer</i> , 2020, 133, 25-28.	1.3	4
82	Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease. <i>European Journal of Haematology</i> , 2021, 107, 642-649.	1.1	4
83	Correcting the misnomers of epithelial-mesenchymal relations. <i>Journal of Surgical Research</i> , 2013, 182, 36-39.	0.8	3
84	Tumor Symbiosis: Gastrointestinal Stromal Tumor as a Host for Primary Peritoneal Mesothelioma. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 879-881.	0.9	3
85	Moving gastrointestinal stromal tumours towards truly personalised precision therapy. <i>Lancet Oncology</i> , The, 2020, 21, 865-867.	5.1	3
86	Patient-Derived Sarcoma Organoids Offer a Novel Platform for Personalized Precision Medicine. <i>Annals of Surgical Oncology</i> , 2022, 29, 7239-7241.	0.7	3
87	Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 2154-2161.	0.9	2
88	Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process. <i>Cancers</i> , 2020, 12, 2375.	1.7	2
89	Commission on Cancer Facility Type is Associated with Overall Survival in Patients with Gastric Adenocarcinoma in the United States. <i>Annals of Surgical Oncology</i> , 2021, 28, 2846-2855.	0.7	2
90	A Solution to Academic Radiology's Experience With Solicitation E-mails From Predatory Journals. <i>American Journal of Roentgenology</i> , 2021, 216, 233-240.	1.0	2

#	ARTICLE	IF	CITATIONS
91	Molecular pathogenesis of biliary tract cancer. , 2017, , 150-159.e2.		1
92	Biomarkers of Bad Biology: Curse or a Blessing?. Annals of Surgical Oncology, 2019, 26, 318-320.	0.7	1
93	Synchronous, Yet Genomically Distinct, GIST Offer New Insights Into Precise Targeting of Tumor Driver Mutations. JCO Precision Oncology, 2021, 5, 525-532.	1.5	1
94	Fluorescence-guided laparoscopic hepatectomy. Annals of Laparoscopic and Endoscopic Surgery, 2016, 1, 10-10.	0.5	1
95	Analysis of over 100,000 patients with cancer for CD274 (PD-L1) amplification: Implications for treatment with immune checkpoint blockade.. Journal of Clinical Oncology, 2018, 36, 47-47.	0.8	1
96	Pregnancy-associated large pelvic desmoid tumor: A case report of fetal-protective strategies and fertility preservation. Gynecologic Oncology Reports, 2022, 39, 100901.	0.3	1
97	Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies. Npj Precision Oncology, 2022, 6, 18.	2.3	1
98	Co-Localization of Gastrointestinal Stromal Tumors (GIST) and Peritoneal Mesothelioma: A Case Series. Annals of Surgical Oncology, 0, , .	0.7	1
99	Pelvic Mass After Prostatectomy. JAMA Surgery, 2014, 149, 741.	2.2	0
100	ASO Author Reflections: Towards Better Metrics for Judging Academic Productivity in Surgical Oncology. Annals of Surgical Oncology, 2018, 25, 620-621.	0.7	0
101	Letter responds to comment on "intention-to-treat analysis in precision oncology: A cautious interpretation". European Journal of Cancer, 2020, 138, 228.	1.3	0
102	Consensus treatment guidelines for urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process.. Journal of Clinical Oncology, 2017, 35, 452-452.	0.8	0
103	A novel t-stage classification system for adrenocortical carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group.. Journal of Clinical Oncology, 2017, 35, 266-266.	0.8	0
104	Guidelines for management of urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process.. Journal of Clinical Oncology, 2017, 35, e15641-e15641.	0.8	0
105	RAS alterations: Next-generation sequencing of 1,526 patients with diverse malignancies reveals prognostic and therapeutic correlates.. Journal of Clinical Oncology, 2018, 36, 12096-12096.	0.8	0
106	Investigation of profile-related evidence determining individualized cancer therapy (I-PREDICT) in heavily pre-treated patients: A role for combinatorial precision cancer therapy.. Journal of Clinical Oncology, 2018, 36, 2531-2531.	0.8	0
107	Re-visiting EGFR amplification as a target for anti-EGFR therapy: Analysis of cell-free circulating tumor DNA in patients with diverse cancers.. Journal of Clinical Oncology, 2018, 36, 12028-12028.	0.8	0
108	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group. VideoEndocrinology, 2018, 5, .	0.1	0